|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMBIM1 |
Gene summary for TMBIM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMBIM1 | Gene ID | 64114 |
| Gene name | transmembrane BAX inhibitor motif containing 1 | |
| Gene Alias | LFG3 | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0001974 | UniProtAcc | A0A024R472 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64114 | TMBIM1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.60e-02 | 1.74e-01 | 0.0155 |
| 64114 | TMBIM1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.91e-32 | 1.54e+00 | -0.1808 |
| 64114 | TMBIM1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.44e-29 | 1.07e+00 | -0.0811 |
| 64114 | TMBIM1 | HTA11_78_2000001011 | Human | Colorectum | AD | 9.68e-15 | 6.37e-01 | -0.1088 |
| 64114 | TMBIM1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.92e-42 | 1.05e+00 | -0.1954 |
| 64114 | TMBIM1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.07e-16 | 2.20e+00 | -0.2602 |
| 64114 | TMBIM1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.75e-18 | 1.69e+00 | -0.2196 |
| 64114 | TMBIM1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.58e-09 | 6.51e-01 | -0.1207 |
| 64114 | TMBIM1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.74e-13 | 6.94e-01 | -0.1526 |
| 64114 | TMBIM1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.78e-30 | 8.14e-01 | -0.1464 |
| 64114 | TMBIM1 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.90e-17 | 5.90e-01 | -0.1001 |
| 64114 | TMBIM1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.03e-21 | 9.70e-01 | -0.059 |
| 64114 | TMBIM1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.15e-10 | 9.01e-01 | -0.1706 |
| 64114 | TMBIM1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.61e-16 | 1.29e+00 | -0.2061 |
| 64114 | TMBIM1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 5.05e-04 | 5.60e-01 | -0.1462 |
| 64114 | TMBIM1 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.23e-05 | 4.77e-01 | -0.0842 |
| 64114 | TMBIM1 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.42e-07 | 3.45e-01 | 0.096 |
| 64114 | TMBIM1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.36e-05 | 6.04e-01 | 0.0528 |
| 64114 | TMBIM1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 3.15e-04 | 4.71e-01 | 0.0131 |
| 64114 | TMBIM1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.92e-05 | 4.82e-01 | 0.0338 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19030777 | Oral cavity | OSCC | negative regulation of protein localization to plasma membrane | 16/7305 | 24/18723 | 5.63e-03 | 2.17e-02 | 16 |
| GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
| GO:19054764 | Oral cavity | OSCC | negative regulation of protein localization to membrane | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
| GO:2001233110 | Oral cavity | LP | regulation of apoptotic signaling pathway | 168/4623 | 356/18723 | 1.35e-20 | 3.02e-18 | 168 |
| GO:2001234110 | Oral cavity | LP | negative regulation of apoptotic signaling pathway | 102/4623 | 224/18723 | 7.22e-12 | 5.58e-10 | 102 |
| GO:007265919 | Oral cavity | LP | protein localization to plasma membrane | 119/4623 | 284/18723 | 1.11e-10 | 6.44e-09 | 119 |
| GO:199077817 | Oral cavity | LP | protein localization to cell periphery | 133/4623 | 333/18723 | 4.42e-10 | 2.21e-08 | 133 |
| GO:0097191110 | Oral cavity | LP | extrinsic apoptotic signaling pathway | 91/4623 | 219/18723 | 2.69e-08 | 9.80e-07 | 91 |
| GO:190547517 | Oral cavity | LP | regulation of protein localization to membrane | 74/4623 | 175/18723 | 2.26e-07 | 6.81e-06 | 74 |
| GO:190307618 | Oral cavity | LP | regulation of protein localization to plasma membrane | 48/4623 | 104/18723 | 1.51e-06 | 3.62e-05 | 48 |
| GO:190437517 | Oral cavity | LP | regulation of protein localization to cell periphery | 55/4623 | 125/18723 | 1.77e-06 | 4.11e-05 | 55 |
| GO:2001236110 | Oral cavity | LP | regulation of extrinsic apoptotic signaling pathway | 63/4623 | 151/18723 | 2.98e-06 | 6.47e-05 | 63 |
| GO:190382813 | Oral cavity | LP | negative regulation of cellular protein localization | 49/4623 | 117/18723 | 3.18e-05 | 4.89e-04 | 49 |
| GO:000862517 | Oral cavity | LP | extrinsic apoptotic signaling pathway via death domain receptors | 37/4623 | 82/18723 | 4.28e-05 | 6.15e-04 | 37 |
| GO:2001237110 | Oral cavity | LP | negative regulation of extrinsic apoptotic signaling pathway | 38/4623 | 97/18723 | 1.11e-03 | 9.13e-03 | 38 |
| GO:190204116 | Oral cavity | LP | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 21/4623 | 49/18723 | 4.00e-03 | 2.59e-02 | 21 |
| GO:190547612 | Oral cavity | LP | negative regulation of protein localization to membrane | 15/4623 | 32/18723 | 5.23e-03 | 3.19e-02 | 15 |
| GO:190307712 | Oral cavity | LP | negative regulation of protein localization to plasma membrane | 12/4623 | 24/18723 | 6.44e-03 | 3.78e-02 | 12 |
| GO:200123329 | Skin | cSCC | regulation of apoptotic signaling pathway | 173/4864 | 356/18723 | 2.25e-20 | 3.44e-18 | 173 |
| GO:200123429 | Skin | cSCC | negative regulation of apoptotic signaling pathway | 101/4864 | 224/18723 | 4.17e-10 | 1.70e-08 | 101 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMBIM1 | SNV | Missense_Mutation | novel | c.792N>A | p.Phe264Leu | p.F264L | Q969X1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| TMBIM1 | SNV | Missense_Mutation | novel | c.806N>T | p.Thr269Ile | p.T269I | Q969X1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMBIM1 | SNV | Missense_Mutation | c.523N>G | p.Met175Val | p.M175V | Q969X1 | protein_coding | deleterious(0) | benign(0.217) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
| TMBIM1 | insertion | Frame_Shift_Ins | novel | c.803_804insTGTGGTGT | p.Thr269ValfsTer41 | p.T269Vfs*41 | Q969X1 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMBIM1 | deletion | Frame_Shift_Del | novel | c.534delN | p.Met178IlefsTer18 | p.M178Ifs*18 | Q969X1 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TMBIM1 | SNV | Missense_Mutation | novel | c.260G>C | p.Gly87Ala | p.G87A | Q969X1 | protein_coding | tolerated(0.62) | benign(0.012) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TMBIM1 | SNV | Missense_Mutation | rs143173370 | c.929G>A | p.Arg310His | p.R310H | Q969X1 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TMBIM1 | SNV | Missense_Mutation | novel | c.707T>C | p.Val236Ala | p.V236A | Q969X1 | protein_coding | deleterious(0.05) | benign(0.012) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TMBIM1 | SNV | Missense_Mutation | c.682A>G | p.Ile228Val | p.I228V | Q969X1 | protein_coding | tolerated(0.38) | benign(0.086) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TMBIM1 | SNV | Missense_Mutation | novel | c.767N>C | p.Leu256Pro | p.L256P | Q969X1 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |